2. Huntington’s Disease Program
  3. HD Research Center
  4. Current Research Studies
  5. Clinical Trial: INVEST-HD

Clinical Trial: INVEST-HD

A Study to Evaluate the Efficacy, Safety, and Tolerability of Votoplam in Huntington’s Disease

For more information, please visit clinicaltrials.gov (external link)

SponsorNovartis
The StudyINVEST-HD is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Votoplam, an oral therapy designed to reduce mutant huntingtin (mHTT) protein by modifying HTT RNA splicing.
Who can participate?• Ages 21–70
• Genetically confirmed Huntington’s disease (CAG ≥40)
• Early symptomatic stage
What is required?• Screening for eligibility
• Daily oral medication (Votoplam or placebo)
• Regular clinic visits for: Neurologic and cognitive assessments, blood tests and biomarkers, MRI ± lumbar puncture
How long does it take?~24–36 months
PhaseIII
ContactDane Weinig
Research Coordinator
(713) 500-7201
[email protected]
[email protected]